|Articles|June 1, 2012

Applied Clinical Trials

  • Applied Clinical Trials-06-01-2012
  • Volume 21
  • Issue 6

Phones Still a Vital Part of Clinical Research

In clinical trials, the need for globally accessible toll-free and other phone numbers for trial functions is vital.

In clinical trials, the need for globally accessible toll-free and other phone numbers for trial functions is vital. But because of the way international telephone carrier services are set up, phone numbers may be left inoperable.

According to Stephen Levenson, Vice President of Global Telecom Testing, international telecommunications companies rent phone lines from local carriers. These companies have no control over the line or service and are dependent on the local carrier. This may not sound problematic, until a number doesn't work. Then it could mean days of downtime to resolve issues.

Levenson's company offers multi-faceted in-country, live human testing of phone numbers. These tests are done within the country to attempt completing outbound calls to ensure the number(s) works. This is different than testing a number by computer, because computers can't determine if customers will be able to call the designated number from in-country local access points, if they can hear clearly, or if other call quality issues are present. Global Telecom Testing offers an additional service through its relationship with locally-based phone carriers to resolve phone issues directly.

Other issues with international calling and their local exchange carrier partners assume that an international telephone number is operational just because it has worked in the past. In addition, some countries or regions have no industry standard or phone company regulation.

Global Telecom Testing's technicians have discovered improper carrier provisioning, improper passcode designation, improper message authentication, echo, static, post dial delay, network inaccessibility, carrier activation failures, and on-site blocking of 800 numbers.

Levenson told Applied Clinical Trials, "What we have found over the past three years is up to 40% of these numbers are not operational when they are handed off to go live. This is a colossal fail for a clinical trial."

—Lisa Henderson

Articles in this issue


Related to this article

© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.